AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC

Phase 3 Clinical Study of AK112 for NSCLC Patients

NCT05184712 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer

NCT05377658 ·Status: RECRUITING ·Phase: PHASE2

A Phase II Trial of AK104 in Advanced Non-Small Cell Lung Cancer

NCT05215067 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Phase III Study of AK112 for NSCLC Patients

NCT06396065 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer

NCT03574649 ·Status: WITHDRAWN ·Phase: PHASE2

A Study of Anti-PD-1 AK105 in Patients With Metastatic Squamous Non-small Cell Lung Cancer

NCT03866993 ·Status: COMPLETED ·Phase: PHASE3

Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel/Carboplatin vs. Paclitaxel /Carboplatin in Stage Ⅱ B and IIIA Squamous Cell Carcinoma of the Lung

NCT01872403 ·Status: UNKNOWN ·Phase: PHASE2

A Study of AK104 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

NCT04647344 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Study to Investigate the Efficacy and Safety of Ivonescimab Combined With Irinotecan Liposome as Second-line Regimen for ES-SCLC

NCT06478043 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

WTX212A Monotherapy and in Combination With PD -1/PD-L1 Monoclonal Antibody

NCT06106152 ·Status: RECRUITING ·Phase: EARLY_PHASE1

S0342: Paclitaxel, Carboplatin, and Cetuximab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00085501 ·Status: COMPLETED ·Phase: PHASE2

A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer

NCT05990127 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3

Neo-Adjuvant Immunotherapy With Nivolumab for Non Small Cell Lung Cancer Patients

NCT03081689 ·Status: COMPLETED ·Phase: PHASE2

Evaluation of a New Anti-cancer Vaccine for Patients With Non-small Cell Lung Cancer, After Tumor Removal by Surgery

NCT01159964 ·Status: TERMINATED ·Phase: PHASE1

Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

NCT00729612 ·Status: COMPLETED ·Phase: PHASE2

Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic Regimen

NCT02475382 ·Status: NO_LONGER_AVAILABLE

Study to Evaluate KOS-1584 in Patients With Advanced or Metastatic Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)

NCT00651508 ·Status: COMPLETED ·Phase: PHASE2

Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK

NCT05266846 ·Status: RECRUITING ·Phase: PHASE2

Anti PD-1 Neo-adjuvant Treatment for NSCLC

NCT02938624 ·Status: COMPLETED ·Phase: PHASE1

Carboplatin and Paclitaxel Combined With Cetuximab and/or IMC-A12 in Patients With Advanced Non-Small Cell Lung Cancer

NCT00986674 ·Status: COMPLETED ·Phase: PHASE2

A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT05741021 ·Status: UNKNOWN ·Phase: PHASE2

Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer

NCT05340309 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer

NCT03158129 ·Status: COMPLETED ·Phase: PHASE2

Chemotherapy Combined with ICIs in First-line Alectinib Failed Patients with ALK-rearranged NSCLC

NCT04997382 ·Status: COMPLETED ·Phase: PHASE2

Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Programmed Death-1 (Pd-L1) <1%

NCT07215962 ·Status: ACTIVE_NOT_RECRUITING